

# Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

NCT06512389

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Centre for Addiction and Mental Health
Enrollment	36 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Meets DSM-5 criteria for AUD.
  - Meets drinking criteria of average weekly consumption  $\geq$  10 standard drinks for women and  $\geq$  15 standard drinks for men over the past 90 days.
  - Willing to take study medication and participate in laboratory sessions requiring self-administration of alcohol
  - Agrees not to use cannabis or illicit drugs during the study period.
  - Able to communicate and provide informed consent in English.
- ... and 4 more (see full listing online)

### Exclusion (15)

- Clinical Institute Withdrawal Assessment (CIWA-Ar) score of 10 or above upon initial assessment
  - History of severe alcohol withdrawal including withdrawal seizures, alcoholic hallucinosis, or delirium tremens
  - Any history of seizures
  - Serious unstable medical condition, including severe hepatic abnormalities
  - Having any clinical condition, drug sensitivity, or prior therapy which, in the investigator's opinion, makes the participant unsuitable for the study
- ... and 10 more (see full listing online)

## Locations (1 total)

---

Centre for Addiction and Mental Health, Toronto, Ontario, Canada